CAMBRIDGE, Mass.--(BUSINESS WIRE)--Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.
Dr. Schuetz’s presentation will feature an update on the ongoing Phase 1 trial of the company’s lead candidate, CTX-471, a fully human agonistic antibody of CD137 being evaluated in patients with advanced solid tumors. Dr. Schuetz will also share the company’s progress on CTX-8371, a novel PD-1/PD-L1 bispecific, which has shown significantly increased activity in preclinical testing compared to PD-1 or PD-L1 monoclonal antibody therapies available commercially.
The presentation details are:
Date: Tuesday, March 3, 2020
Time: 11:00 – 11:25 a.m. ET
Location: Boston Marriott Copley Place
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.
